Skip to main content
. Author manuscript; available in PMC: 2014 Jul 30.
Published in final edited form as: J Natl Compr Canc Netw. 2013 Jul;11(7):766–772. doi: 10.6004/jnccn.2013.0099

Figure 1.

Figure 1

Combinatorial strategies simultaneously use vaccines to prime tumor antigen-specific T cells and other agents to block T-cell inhibitory signals. Commercial grade agents are available or will become available to test in combinations. Examples include: 1) bevacizumab; 2) celecoxib; 3) GCS-100; 4) GC-1008; 5) cyclophosphamide, daclizumab, denileukin diftitox; 6) 1-MT; 7) BMS-936558, BMS-936559, CT-011, MPDL3280A, MEDI4736, AMP-224, MK-3475; 8) ipilimumab, tremelimumab; and 9) BMS anti-lag-3.